Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2005

View Archived Issues

Bayer claims novel vanilloid VR1 receptor antagonists for urological disorders

Recent patents report new treatments for depression, anxiety, psychotic disorders, etc.

BMS describes novel agents for osteoporosis, among other indications

Anxiolytic activity of ELB-139 in animal models described

OSI to acquire Eyetech Pharmaceuticals

Phase I trial results show the safety and pharmacokinetics of PRO-140 in healthy subjects

Fludelone is effective in preclinical models of multiple myeloma

Preclinical investigation of therapies for CRPS-I

Enrollment opens in phase II heparin replacement study for rNAPc2

BioSite obtains license for cardiovascular disease biomarker

Swedish Cancer Institute commences new phase II study in patients with BAC

Dyax and Merck KGaA enter license agreement for phage display libraries

Scios launches recommended use initiative for Natrecor

Endomorphin-2 and antiinflammatory cytokine gene therapy evoke analgesia

Preclinical evidence of antiallodynic effects of ACV-1

Chronic administration of CP-55940 relieves tumor-evoked mechanical hyperalgesia

Zaprinast alone and in combination with morphine facilitates antinociception

Copromotion agreement for Xifaxan ends

Lorus Therapeutics selects subclass of lead molecules from anticancer program

Canadian approval for phase III study of Multikine in head and neck cancer

Phase II/III MS study of MBP-8298 to be extended to Sweden

V-1003 enters phase II study for acute postoperative pain

Merck & Co. selects lead antibody for development for asthma

No drug interactions between rilpivirine and tenofovir disoproxil fumarate in healthy volunteers

Neuropeptide B modulates body weight homeostasis and inflammatory pain responses in mice

Aceon receives FDA approval for new indication

Cell Therapeutics decides on limited population for U.S. filing of Xyotax

Nevanac approved for pain and inflammation related to cataract surgery

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...